Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)

David Crossman; Alexander M K Rothman

doi:10.21037/jtd.2018.07.50

Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)

David Crossman, Alexander M K Rothman

School of Medicine

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	S3084-S3087
Journal	Journal of Thoracic Disease
Volume	10
Issue number	Suppl 26
DOIs	https://doi.org/10.21037/jtd.2018.07.50
Publication status	Published - 18 Sept 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.21037/jtd.2018.07.50

Cite this

@article{1bd8f618e74845cdaeca476d27fd304e,

title = "Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)",

author = "David Crossman and Rothman, \{Alexander M K\}",

year = "2018",

month = sep,

day = "18",

doi = "10.21037/jtd.2018.07.50",

language = "English",

volume = "10",

pages = "S3084--S3087",

journal = "Journal of Thoracic Disease",

issn = "2072-1439",

publisher = "AME Publishing Company",

number = "Suppl 26",

}

TY - JOUR

T1 - Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)

AU - Crossman, David

AU - Rothman, Alexander M K

PY - 2018/9/18

Y1 - 2018/9/18

UR - https://www.scopus.com/pages/publications/85053802379

U2 - 10.21037/jtd.2018.07.50

DO - 10.21037/jtd.2018.07.50

M3 - Editorial

C2 - 30370085

SN - 2072-1439

VL - 10

SP - S3084-S3087

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

IS - Suppl 26

ER -

Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)

UN SDGs

Access to Document

Other files and links

Cite this